Online inquiry

IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12728MR)

This product GTTS-WQ12728MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets DLL4&VEGFA gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_019074.4; NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 54567; 7422
UniProt ID Q9NR61; P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ12728MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6594MR IVTScrip™ mRNA-Anti-DPEP3, DC-1728001(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA DC-1728001
GTTS-WQ4712MR IVTScrip™ mRNA-Anti-MAPT, BMS-986168(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-986168
GTTS-WQ3950MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BFCR-4350-A
GTTS-WQ13483MR IVTScrip™ mRNA-Anti-IgG-Fc, PRTX-100(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PRTX-100
GTTS-WQ7268MR IVTScrip™ mRNA-Anti-VEGFA, FP3 protein(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA FP3 protein
GTTS-WQ8101MR IVTScrip™ mRNA-Anti-TNFRSF10B, HGS-ETR2(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HGS-ETR2
GTTS-WQ5877MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, CIFN(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CIFN
GTTS-WQ8336MR IVTScrip™ mRNA-Anti-TFRC, HN-66000(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA HN-66000
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW